GlassScriptPhysician profile
Steven J Scherr
NPI 1083654792
$569.68
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $71.85 · 2021: $62.73 · 2022: $97.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $252.33 | 2019-2022 | |
| Astellas Pharma US INC | $109.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $50.36 | 2019-2020 | |
| Amgen INC. | $41.83 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $31.70 | 2019-2020 | |
| Pfizer INC. | $29.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.84 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.87 | 2022 | |
| Radius Health, INC. | $13.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Scherr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.